Close menu




NOVO NORDISK A/S

Photo credits: pixabay.com

Commented by Stefan Feulner on November 21st, 2023 | 07:00 CET

Novo Nordisk, Defence Therapeutics, Morphosys - The biotechs are coming

  • Biotechnology
  • Pharma
  • Innovations

The capital-intensive biotech sector was hit particularly hard when the US Federal Reserve began the massive interest rate hikes from zero to 5.5% in the first quarter of 2022. Since then, the broad-based Nasdaq Biotech Index has lost around 20% of its value. With the end of the strict monetary policy, this sector is now likely to experience a revival on the stock market. There is significant catching-up potential, especially among second-tier stocks.

Read

Commented by Stefan Feulner on October 16th, 2023 | 06:50 CEST

Lots of activity in the biotech sector - Novo Nordisk, Defence Therapeutics, Morphosys

  • Biotechnology
  • Pharma
  • Innovations

Despite the rather gloomy economic outlook on the one hand and high interest rates on the other, there is significant movement in the capital-intensive biotechnology sector. After Amgen successfully concluded the acquisition of Horizon Therapeutics for USD 116.50 per share or a total volume of around USD 27.8 billion, further investments by Big Pharma in innovative and promising technologies will likely follow soon.

Read